• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

临床试验中类风湿关节炎的放射学进展:行业开展试验的系统性文献复习。

Radiographic progression in clinical trials in rheumatoid arthritis: a systemic literature review of trials performed by industry.

机构信息

Internal Medicine, The Catholic University of Korea, Seoul, Korea (the Republic of).

Rheumatology, St. Vincent's Hospital, The Catholic University of Korea, Suwon, Korea (the Republic of).

出版信息

RMD Open. 2020 Jul;6(2). doi: 10.1136/rmdopen-2020-001277.

DOI:10.1136/rmdopen-2020-001277
PMID:32669455
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7425197/
Abstract

OBJECTIVES

To summarise radiographic data in randomised controlled trials (RCTs) as part of the radiographic inhibition claim of disease-modifying antirheumatic drugs (DMARDs) approved for patients with rheumatoid arthritis (RA).

METHODS

A systemic literature review was performed using the Medline database from 1994 to February 2020. The results were grouped based on the scoring methods (Sharp, Genant modification, van der Heijde modification) and RA patient populations.

RESULTS

One hundred sixty-eight publications were selected. After detailed assessment, 52 RCTs (7 methotrexate (MTX)-naive, 23 MTX inadequate response (IR), 9 DMARDs IR and 3 tumour necrosis factor-alpha inhibitors (TNFi) IR studies) were finally included. Information on patient population, scoring method used, reader reliability, statistical analyses and detailed radiographic data on baseline and change scores over multiple follow-up periods are presented.

CONCLUSION

The data gathered in this review serve as a repository for the design of future trials with radiographic damage as an outcome.

摘要

目的

总结随机对照试验(RCT)中的影像学数据,作为获批用于类风湿关节炎(RA)患者的改善病情抗风湿药物(DMARDs)影像学抑制疗效主张的一部分。

方法

从 1994 年至 2020 年 2 月,使用 Medline 数据库进行系统文献回顾。根据评分方法(Sharp、Genant 改良、van der Heijde 改良)和 RA 患者人群对结果进行分组。

结果

共选择了 168 篇出版物。经过详细评估,最终纳入 52 项 RCT(7 项甲氨蝶呤(MTX)初治、23 项 MTX 应答不足(IR)、9 项 DMARDs IR 和 3 项肿瘤坏死因子-α抑制剂(TNFi)IR 研究)。介绍了患者人群、使用的评分方法、观察者可靠性、统计分析以及基线和多次随访期间变化评分的详细影像学数据。

结论

本综述中收集的数据为未来以影像学损伤为结局的试验设计提供了依据。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ff5/7425197/e9f28218e9d6/rmdopen-2020-001277f01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ff5/7425197/e9f28218e9d6/rmdopen-2020-001277f01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ff5/7425197/e9f28218e9d6/rmdopen-2020-001277f01.jpg

相似文献

1
Radiographic progression in clinical trials in rheumatoid arthritis: a systemic literature review of trials performed by industry.临床试验中类风湿关节炎的放射学进展:行业开展试验的系统性文献复习。
RMD Open. 2020 Jul;6(2). doi: 10.1136/rmdopen-2020-001277.
2
A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.阿达木单抗、依那西普和英夫利昔单抗治疗成人类风湿关节炎有效性的系统评价及其成本效益的经济学评估。
Health Technol Assess. 2006 Nov;10(42):iii-iv, xi-xiii, 1-229. doi: 10.3310/hta10420.
3
Sarilumab for Previously-Treated Moderate or Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.依那西普治疗中重度特应性皮炎的疗效与安全性:一项网状 Meta 分析
Pharmacoeconomics. 2018 Dec;36(12):1427-1437. doi: 10.1007/s40273-018-0677-7.
4
Alternative tumour necrosis factor inhibitors (TNFi) or abatacept or rituximab following failure of initial TNFi in rheumatoid arthritis: the SWITCH RCT.类风湿关节炎初始 TNFi 治疗失败后应用替代肿瘤坏死因子抑制剂(TNFi)或阿巴西普或利妥昔单抗:SWITCH RCT。
Health Technol Assess. 2018 Jun;22(34):1-280. doi: 10.3310/hta22340.
5
Circulating serum interleukin-6, serum chitinase-3-like protein-1, and plasma vascular endothelial growth factor are not predictive for remission and radiographic progression in patients with early rheumatoid arthritis: post-hoc explorative and validation studies based on the CIMESTRA and OPERA trials.循环血清白细胞介素-6、血清几丁质酶-3样蛋白-1和血浆血管内皮生长因子不能预测早期类风湿关节炎患者的缓解和影像学进展:基于CIMESTRA和OPERA试验的事后探索性和验证性研究
Scand J Rheumatol. 2018 Jul;47(4):259-269. doi: 10.1080/03009742.2017.1376107. Epub 2018 Jan 16.
6
Baricitinib for Previously Treated Moderate or Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.巴瑞替尼治疗既往治疗的中度或重度类风湿关节炎:一项 NICE 单技术评估的证据审查组观点。
Pharmacoeconomics. 2018 Jul;36(7):769-778. doi: 10.1007/s40273-018-0616-7.
7
Structural joint damage and hand bone loss in patients with rheumatoid arthritis.类风湿关节炎患者的关节结构损伤与手部骨质流失
Dan Med J. 2018 Mar;65(3).
8
Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study.在未使用过改善病情抗风湿药(DMARD)、具有不良预后因素的早期、活动期类风湿关节炎患者中,聚乙二醇化赛妥珠单抗联合剂量优化的甲氨蝶呤的疗效:来自随机、双盲、安慰剂对照III期研究C-EARLY的1年结果
Ann Rheum Dis. 2017 Jan;76(1):96-104. doi: 10.1136/annrheumdis-2015-209057. Epub 2016 May 10.
9
Radiographic and clinical outcomes following etanercept monotherapy in Japanese methotrexate-naïve patients with active rheumatoid arthritis.依那西普单药治疗对日本甲氨蝶呤初治的活动期类风湿关节炎患者的影像学和临床结局。
Mod Rheumatol. 2020 Mar;30(2):259-268. doi: 10.1080/14397595.2019.1589918. Epub 2019 Mar 29.
10
The first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression.在未使用甲氨蝶呤且预后因素较差的早期类风湿性关节炎患者中开展的第一项关于赛妥珠单抗聚乙二醇化修饰物的双盲、随机、平行组研究——C-OPERA研究,显示出对影像学进展的抑制作用。
Ann Rheum Dis. 2016 Jan;75(1):75-83. doi: 10.1136/annrheumdis-2015-207511. Epub 2015 Jul 2.

引用本文的文献

1
Arthritis Mutilans: A Devastating Manifestation of Psoriatic Disease Without Dactylitis in a 61-Year-Old Patient.毁形性关节炎:一名61岁无指(趾)炎的银屑病患者的银屑病性疾病的毁灭性表现
Cureus. 2025 Jul 22;17(7):e88502. doi: 10.7759/cureus.88502. eCollection 2025 Jul.
2
PET in the characterization of immune diseases and development of therapeutics.正电子发射断层扫描(PET)在免疫疾病的特征描述及治疗方法的研发中的应用
Oxf Open Immunol. 2025 May 24;6(1):iqaf005. doi: 10.1093/oxfimm/iqaf005. eCollection 2025.
3
Remission versus low disease activity as treatment targets in rheumatoid arthritis: how to strike the right balance between too strict and too lenient targets? A meta-epidemiological study of individual patient data.

本文引用的文献

1
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update.EULAR 推荐的类风湿关节炎治疗策略:2019 年更新版(使用合成和生物疾病修正抗风湿药物)
Ann Rheum Dis. 2020 Jun;79(6):685-699. doi: 10.1136/annrheumdis-2019-216655. Epub 2020 Jan 22.
2
Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan.在对甲氨蝶呤应答不足的类风湿关节炎患者中,培非替尼(ASP015K)的疗效和安全性:日本一项 III 期随机、双盲、安慰剂对照试验(RAJ4)的结果。
Ann Rheum Dis. 2019 Oct;78(10):1305-1319. doi: 10.1136/annrheumdis-2019-215164. Epub 2019 Jul 26.
3
缓解与低疾病活动度作为类风湿关节炎的治疗目标:如何在过于严格和过于宽松的目标之间取得恰当平衡?一项基于个体患者数据的荟萃流行病学研究。
RMD Open. 2024 Nov 7;10(4):e004387. doi: 10.1136/rmdopen-2024-004387.
4
Approaches to optimize analyses of multidimensional ordinal MRI data in osteoarthritis research: A perspective.骨关节炎研究中优化多维有序MRI数据分析的方法:一种观点。
Osteoarthr Cartil Open. 2024 Mar 27;6(2):100465. doi: 10.1016/j.ocarto.2024.100465. eCollection 2024 Jun.
5
Deep learning enables automatic detection of joint damage progression in rheumatoid arthritis-model development and external validation.深度学习能够自动检测类风湿性关节炎中关节损伤的进展——模型开发与外部验证。
Rheumatology (Oxford). 2025 Mar 1;64(3):1068-1076. doi: 10.1093/rheumatology/keae215.
6
Remission definitions guiding immunosuppressive therapy in rheumatoid arthritis: which is best fitted for the purpose?缓解定义指导类风湿关节炎的免疫抑制治疗:哪种最适合该目的?
RMD Open. 2024 Mar 4;10(1):e003972. doi: 10.1136/rmdopen-2023-003972.
7
Disease activity-guided dose optimization including discontinuation of TNF inhibitors in rheumatoid arthritis is effective for up to 10 years: an observational follow-up of the DRESS study.疾病活动度引导的剂量优化(包括类风湿关节炎中肿瘤坏死因子抑制剂的停用)长达10年有效:DRESS研究的观察性随访
Rheumatology (Oxford). 2025 Feb 1;64(2):533-540. doi: 10.1093/rheumatology/keae103.
8
Time-integrated Cumulative Parameters Predictive of Radiographic Progression of Rheumatoid Arthritis: Real-world Data From a Prospective Single-center Cohort.预测类风湿关节炎影像学进展的时间积分累积参数:来自前瞻性单中心队列的真实世界数据
J Rheum Dis. 2022 Apr 1;29(2):98-107. doi: 10.4078/jrd.2022.29.2.98.
9
Cartilage evaluation by ultrasonography in patients with rheumatoid arthritis: a scoping review.类风湿关节炎患者软骨的超声评估:一项范围综述
Inflamm Regen. 2023 Jul 4;43(1):34. doi: 10.1186/s41232-023-00286-2.
10
Artificial intelligence and the future of radiographic scoring in rheumatoid arthritis: a viewpoint.人工智能与类风湿关节炎影像学评分的未来:观点
Arthritis Res Ther. 2022 Dec 12;24(1):268. doi: 10.1186/s13075-022-02972-x.
Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double-Blind, Randomized Controlled Trial.乌帕替尼治疗甲氨蝶呤应答不足的类风湿关节炎患者的 III 期、双盲、随机对照研究结果。
Arthritis Rheumatol. 2019 Nov;71(11):1788-1800. doi: 10.1002/art.41032. Epub 2019 Aug 28.
4
Diagnosis and Management of Rheumatoid Arthritis: A Review.类风湿关节炎的诊断与治疗:综述。
JAMA. 2018 Oct 2;320(13):1360-1372. doi: 10.1001/jama.2018.13103.
5
Secukinumab in Active Rheumatoid Arthritis after Anti-TNFα Therapy: A Randomized, Double-Blind Placebo-Controlled Phase 3 Study.抗TNFα治疗后司库奇尤单抗用于活动性类风湿关节炎:一项随机、双盲、安慰剂对照的3期研究。
Rheumatol Ther. 2017 Dec;4(2):475-488. doi: 10.1007/s40744-017-0086-y. Epub 2017 Nov 14.
6
52-week results of the phase 3 randomized study comparing SB4 with reference etanercept in patients with active rheumatoid arthritis.在活动性类风湿关节炎患者中比较SB4与参比药物依那西普的3期随机研究的52周结果。
Rheumatology (Oxford). 2017 Dec 1;56(12):2093-2101. doi: 10.1093/rheumatology/kex269.
7
Comparing biosimilar SB2 with reference infliximab after 54 weeks of a double-blind trial: clinical, structural and safety results.双盲试验54周后生物类似药SB2与参比英夫利昔单抗的对比:临床、结构及安全性结果
Rheumatology (Oxford). 2017 Oct 1;56(10):1771-1779. doi: 10.1093/rheumatology/kex254.
8
Sirukumab for rheumatoid arthritis: the phase III SIRROUND-D study.用于类风湿性关节炎的sirukumab:III期SIRROUND-D研究。
Ann Rheum Dis. 2017 Dec;76(12):2001-2008. doi: 10.1136/annrheumdis-2017-211328. Epub 2017 Aug 30.
9
Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis.巴利替尼与安慰剂或阿达木单抗治疗类风湿关节炎的疗效比较。
N Engl J Med. 2017 Feb 16;376(7):652-662. doi: 10.1056/NEJMoa1608345.
10
Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease-Modifying Antirheumatic Drug Treatment.巴利昔替尼、甲氨蝶呤或联合治疗类风湿关节炎患者,且这些患者既往无或有限的疾病修饰抗风湿药物治疗史。
Arthritis Rheumatol. 2017 Mar;69(3):506-517. doi: 10.1002/art.39953.